March 2, 2023Open Access

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

Key Points

Key points are not available for this paper at this time.

Abstract

Combination therapy had a higher efficacy than EGFR-TKI alone for patients with NSCLC having concomitant EGFR and TP53 mutations. Future prospective clinical trials are needed to determine the role of combination therapy for this patient population.

Bookmark

View Full Paper

Cite This Study

Sun et al. (Thu,) studied this question.

synapsesocial.com/papers/69dea2f76bae133e7de946b1 https://doi.org/https://doi.org/10.1186/s12885-023-10637-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations2013 · 3,199 citations
2Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model2003 · 67 citations
3<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics2016 · 105 citations
4TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis2016 · 100 citations
5Tumor Suppressive Functions of p532009 · 576 citations

Bookmark

View Full Paper